Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00114270 · ClinicalTrials.gov registry record · NA
Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density
A NA study, sponsored by University of Virginia.
- Completed
- Registry status
- NA
- Development phase
NCT00114270: Completed NA study, sponsored by University of Virginia.
NCT00114270 is a NA study that has completed, run by University of Virginia. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00114270, a NA study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may prevent breast cancer by lowering the amount of estrogen the body makes. Zoledronate may prevent bone loss caused by letrozole. Giving letrozole together with zoledronate may prevent breast cancer and reduce bone loss. PURPOSE: This randomized clinical trial is studying letrozole and zoledronate to see how well they work compared to letrozole and placebo or placebo alone in treating healthy postmenopausal women with high breast density.
Interventions
- DRUG letrozole
- DRUG zoledronic acid
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-05 |
| Est. Completion | 2007-06 |
| Phase | NA |
What the finished NCT00114270 record still lists
NCT00114270 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which letrozole is the first listed.
NCT00114270 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00114270 about?
NCT00114270 is a clinical study titled "Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density". RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may prevent breast cancer by lowering the amount of estrogen the body makes. Zoledronate may prevent bone...
What is the current status of trial NCT00114270?
This trial is currently completed. It is a NA study. The study started on 2004-05. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00114270?
The interventions under investigation include: letrozole (DRUG), zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT00114270?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia